[go: up one dir, main page]

WO2003024446A1 - Inhibiteur du stress oxydatif et methode de mesure du stress oxydatif - Google Patents

Inhibiteur du stress oxydatif et methode de mesure du stress oxydatif Download PDF

Info

Publication number
WO2003024446A1
WO2003024446A1 PCT/JP2002/009087 JP0209087W WO03024446A1 WO 2003024446 A1 WO2003024446 A1 WO 2003024446A1 JP 0209087 W JP0209087 W JP 0209087W WO 03024446 A1 WO03024446 A1 WO 03024446A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxidation stress
diseases
brain
various
measuring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/009087
Other languages
English (en)
Japanese (ja)
Inventor
Yorihiro Yamamoto
Chizuko Takahashi
Kazutoshi Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Priority to JP2003528542A priority Critical patent/JPWO2003024446A1/ja
Publication of WO2003024446A1 publication Critical patent/WO2003024446A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un inhibiteur du stress oxydatif contenant en tant qu'ingrédient actif un dérivé de pyrazolone, représenté par la formule (I) telle que définie dans la description, ou son sel pharmaceutiquement acceptable. L'invention se rapporte également à une méthode de mesure du stress oxydatif caractérisée en ce qu'elle fait appel à un acide gras monoinsaturé, à de l'ubiquinone-10 ou un à hydropéroxyde d'ester de cholestérol dans le plasma en tant que marqueur. L'invention concerne en outre une méthode d'examen clinique et une méthode d'évaluation de médicament. Le médicament selon l'invention peut servir à prévenir/traiter différentes maladies dues au stress oxydatif (telles que les maladies ischémiques et diverses maladies leur étant liées, à savoir, les maladies cérébrovasculaires telles que l'infarctus cérébral et l'attaque cérébrale, l'hypofonctionnement cérébral et la démence vasculaire, diverses maladies cérébrales associées au vieillissement telles que les lésions tissulaires cérébrovasculaires, divers troubles circulatoires périphériques fondés sur l'ischémie cardiomusculaire tels que l'infarctus cardiomusculaire et l'insuffisance cardiaque, l'insuffisance hépatique et le diabète). Ladite méthode de mesure du stress oxydatif permet de mesurer le stress oxydatif de manière précise et quantitative. Par conséquent, elle peut être employée pour effectuer des examens cliniques et évaluer des médicaments.
PCT/JP2002/009087 2001-09-11 2002-09-06 Inhibiteur du stress oxydatif et methode de mesure du stress oxydatif Ceased WO2003024446A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003528542A JPWO2003024446A1 (ja) 2001-09-11 2002-09-06 酸化ストレス抑制剤および酸化ストレスの測定方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-275466 2001-09-11
JP2001275466 2001-09-11
JP2001-275467 2001-09-11
JP2001275467 2001-09-11

Publications (1)

Publication Number Publication Date
WO2003024446A1 true WO2003024446A1 (fr) 2003-03-27

Family

ID=26622015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009087 Ceased WO2003024446A1 (fr) 2001-09-11 2002-09-06 Inhibiteur du stress oxydatif et methode de mesure du stress oxydatif

Country Status (2)

Country Link
JP (1) JPWO2003024446A1 (fr)
WO (1) WO2003024446A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080583A1 (fr) * 2002-03-27 2003-10-02 Mitsubishi Pharma Corporation Medicament pour prevenir et/ou traiter une cardiomyopathie
JP2004307364A (ja) * 2003-04-03 2004-11-04 Yuutoku Yakuhin Kogyo Kk 経皮吸収貼付剤
WO2005046680A1 (fr) * 2003-11-12 2005-05-26 Lead Chemical Co., Ltd. Agent protecteur cerebral du type administre par absorption percutanee
WO2005054205A1 (fr) * 2003-12-05 2005-06-16 Tokai University Educational System Inhibiteur de production de modificateurs de proteines
WO2005122033A1 (fr) * 2004-06-08 2005-12-22 Intellectual Property Bank Corp. Appareil d’information totale médicale et système d’information totale médicale
JP2006119036A (ja) * 2004-10-22 2006-05-11 Fuso Pharmaceutical Industries Ltd 血中脂肪酸濃度測定による心疾患の早期診断方法
JP2006298774A (ja) * 2005-04-15 2006-11-02 Lead Chemical Co Ltd 経皮吸収型フリーラジカル抑制製剤
JP2007225607A (ja) * 2006-01-27 2007-09-06 Prima Meat Packers Ltd 抗ストレス薬剤のスクリーニング方法及び有効性の判定方法
WO2010087306A1 (fr) 2009-01-29 2010-08-05 株式会社林原生物化学研究所 Agent anti-maladie neurodégénérative
US7977366B2 (en) * 2003-10-14 2011-07-12 Cornell Research Foundation, Inc. Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation
US8273882B2 (en) 2008-05-23 2012-09-25 Novartis Ag Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
CN107365315A (zh) * 2016-05-11 2017-11-21 国药集团国瑞药业有限公司 一种吡唑类化合物、其晶型及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62108814A (ja) * 1985-11-07 1987-05-20 Mitsubishi Chem Ind Ltd 過酸化脂質生成抑制剤
EP0249735A2 (fr) * 1986-05-20 1987-12-23 A. Nattermann & Cie. GmbH Préparations pharmaceutiques contenant comme agent actif la 2-phényl-1,2-benzisosélénazol-3(2H)-one, pour le traitement des maladies causées par le stress oxydant
JPH03215425A (ja) * 1990-01-16 1991-09-20 Mitsubishi Kasei Corp 抗潰瘍剤
EP0633025A1 (fr) * 1993-07-07 1995-01-11 Mitsubishi Chemical Corporation Composition pharmaceutique contenant du 3-méthyl-1-phényl-2-pyrazolin-5-one pour le traitement des maladies ophthalmiques
WO1999063341A2 (fr) * 1998-05-29 1999-12-09 Nikken Foods Co., Ltd. Utilisation du graphique diagnostique de la tension d'ordre oxydatif comme indicateur de sante pour evaluer la tension d'ordre oxydatif et son controle chez l'homme
WO1999064424A1 (fr) * 1998-06-09 1999-12-16 Takara Shuzo Co., Ltd. Agents therapeutiques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62108814A (ja) * 1985-11-07 1987-05-20 Mitsubishi Chem Ind Ltd 過酸化脂質生成抑制剤
EP0249735A2 (fr) * 1986-05-20 1987-12-23 A. Nattermann & Cie. GmbH Préparations pharmaceutiques contenant comme agent actif la 2-phényl-1,2-benzisosélénazol-3(2H)-one, pour le traitement des maladies causées par le stress oxydant
JPH03215425A (ja) * 1990-01-16 1991-09-20 Mitsubishi Kasei Corp 抗潰瘍剤
EP0633025A1 (fr) * 1993-07-07 1995-01-11 Mitsubishi Chemical Corporation Composition pharmaceutique contenant du 3-méthyl-1-phényl-2-pyrazolin-5-one pour le traitement des maladies ophthalmiques
WO1999063341A2 (fr) * 1998-05-29 1999-12-09 Nikken Foods Co., Ltd. Utilisation du graphique diagnostique de la tension d'ordre oxydatif comme indicateur de sante pour evaluer la tension d'ordre oxydatif et son controle chez l'homme
WO1999064424A1 (fr) * 1998-06-09 1999-12-16 Takara Shuzo Co., Ltd. Agents therapeutiques

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080583A1 (fr) * 2002-03-27 2003-10-02 Mitsubishi Pharma Corporation Medicament pour prevenir et/ou traiter une cardiomyopathie
JP2004307364A (ja) * 2003-04-03 2004-11-04 Yuutoku Yakuhin Kogyo Kk 経皮吸収貼付剤
US7977366B2 (en) * 2003-10-14 2011-07-12 Cornell Research Foundation, Inc. Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation
KR101008052B1 (ko) * 2003-11-12 2011-01-13 리도 케미칼 가부시키가이샤 경피흡수형 뇌 보호제
WO2005046680A1 (fr) * 2003-11-12 2005-05-26 Lead Chemical Co., Ltd. Agent protecteur cerebral du type administre par absorption percutanee
US8076368B2 (en) 2003-11-12 2011-12-13 Lead Chemical Co., Ltd, Percutaneous absorption type cerebral protective agent
JPWO2005046680A1 (ja) * 2003-11-12 2007-06-14 リードケミカル株式会社 経皮吸収型脳保護剤
WO2005054205A1 (fr) * 2003-12-05 2005-06-16 Tokai University Educational System Inhibiteur de production de modificateurs de proteines
KR101205748B1 (ko) 2003-12-05 2012-11-28 토카이 유니버시티 에듀케이셔널시스템 단백질 개질물 형성 저해제
JP4837992B2 (ja) * 2003-12-05 2011-12-14 学校法人東海大学 蛋白修飾物生成抑制剤
JPWO2005054205A1 (ja) * 2003-12-05 2007-06-28 学校法人東海大学 蛋白修飾物生成抑制剤
EP1693369A4 (fr) * 2003-12-05 2011-06-22 Univ Tokai Educational System Inhibiteur de production de modificateurs de proteines
JPWO2005122033A1 (ja) * 2004-06-08 2008-07-31 有喜 北岡 医療総合情報装置及び医療総合情報システム
WO2005122033A1 (fr) * 2004-06-08 2005-12-22 Intellectual Property Bank Corp. Appareil d’information totale médicale et système d’information totale médicale
JP2006119036A (ja) * 2004-10-22 2006-05-11 Fuso Pharmaceutical Industries Ltd 血中脂肪酸濃度測定による心疾患の早期診断方法
JP2006298774A (ja) * 2005-04-15 2006-11-02 Lead Chemical Co Ltd 経皮吸収型フリーラジカル抑制製剤
JP2007225607A (ja) * 2006-01-27 2007-09-06 Prima Meat Packers Ltd 抗ストレス薬剤のスクリーニング方法及び有効性の判定方法
US8273882B2 (en) 2008-05-23 2012-09-25 Novartis Ag Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
US8674099B2 (en) 2008-05-23 2014-03-18 Novartis Ag Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
WO2010087306A1 (fr) 2009-01-29 2010-08-05 株式会社林原生物化学研究所 Agent anti-maladie neurodégénérative
CN107365315A (zh) * 2016-05-11 2017-11-21 国药集团国瑞药业有限公司 一种吡唑类化合物、其晶型及其制备方法

Also Published As

Publication number Publication date
JPWO2003024446A1 (ja) 2004-12-24

Similar Documents

Publication Publication Date Title
Wiley et al. The metabolic roots of senescence: mechanisms and opportunities for intervention
WO2003024446A1 (fr) Inhibiteur du stress oxydatif et methode de mesure du stress oxydatif
Shiina et al. Acute effect of oral flavonoid-rich dark chocolate intake on coronary circulation, as compared with non-flavonoid white chocolate, by transthoracic Doppler echocardiography in healthy adults
Riegger et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
Virdis et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension
Widlansky et al. The clinical implications of endothelial dysfunction
Huang et al. Sterculic acid antagonizes 7-ketocholesterol-mediated inflammation and inhibits choroidal neovascularization
JP2004210797A (ja) アムロジピン及びアトルバスタチンを含む治療用の組み合わせ
Alañón et al. Acute study of dose-dependent effects of (−)-epicatechin on vascular function in healthy male volunteers: A randomized controlled trial
JP2005518419A (ja) ポリ不飽和ケトンを乾癬の治療に使用する方法
Karatzis et al. Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina
Galetta et al. Endothelium-dependent vasodilation and carotid artery wall remodeling in athletes and sedentary subjects
ES2575218T3 (es) Método de tratamiento de enfermedades neurodegenerativas o neuromusculares degenerativas y agente terapéutico para tratar las mismas
KR20170066432A (ko) 정신병적 장애를 치료하기 위한 방법 및 조성물
Ma et al. Endothelial dysfunction associated with left ventricular diastolic dysfunction in patients with coronary heart disease
Dumont et al. Improvement of endothelial function in insulin-resistant carotid arteries treated with pravastatin
Frey et al. Thiamidol: A breakthrough innovation in the treatment of hyperpigmentation
Kurata et al. Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
US20130338203A1 (en) TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
Studinger et al. Effect of vitamin E on carotid artery elasticity and baroreflex gain in young, healthy adults
Rafidah et al. Blood pressure variability and arterial elasticity in hyperlipidaemic subjects
Voronkov et al. Cardiotropic properties of chromone-3-aldehyde derivatives under an experimental cardiac infarction complicated with hypercholesterolemia
Nouri-Majalan et al. Relationship between serum homocysteine and other parameters in renal transplant patients
EA005245B1 (ru) Комбинация карбоксиалкиловых эфиров и гипотензивных агентов и фармацевтическое применение
US20080255206A1 (en) Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003528542

Country of ref document: JP

122 Ep: pct application non-entry in european phase